Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19049374 | 0.87 | L3MBTL1 (0.48) | DRD3L3MBTL1DRD2CYP2D6GSK3B | |
| SCHEMBL19002794 | 0.85 | DRD3 (0.47) | DRD3PDE2ARAB9ALMNAALDH1A1 | |
| SCHEMBL19002798 | 0.84 | DRD3 (0.65) | DRD3DRD2 | |
| SCHEMBL19002675 | 0.84 | L3MBTL1 (0.45) | DRD3L3MBTL1DRD2CYP2D6GSK3B | |
| SCHEMBL19002795 | 0.83 | DRD3 (0.48) | DRD3PDE2AUSP30NPC1KMT2A | |
| SCHEMBL19002800 | 0.83 | DRD3 (0.48) | DRD3PDE2AUSP30RAB9ANPC1 | |
| SCHEMBL14035660 | 0.82 | USP30 (0.51) | DRD3USP30RAB9ALMNAALDH1A1 | |
| SCHEMBL7311598 | 0.82 | DRD2 (0.59) | L3MBTL1DRD2CYP2D6USP30RAB9A | |
| SCHEMBL21438214 | 0.82 | CYP2D6 (0.44) | DRD3L3MBTL1DRD2CYP2D6GSK3B | |
| SCHEMBL3345708 | 0.80 | DRD3 (0.44) | DRD3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| CN-1050839-C | Novel sulfonylamino pyrimidines | HOFFMANN LA ROCHE (CH) | 2000-03-29 | — | — | CN | disclosed |
| CN-1106007-A | Novel sulfonylamino pyrimidines | HOFFMANN LA ROCHE (CH) | 1995-08-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | DRD3 4860/4885L3MBTL1 4204/4885DRD2 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.